A Federal Judge has invalidated a major patent by Omni MedSci Inc.. Apple challenged this patent that was holding them back in introducing an Apple Watch feature that could track blood related metrics include glucose monitoring.

• All patent Claims of U.S. Patent 10,517,484 were considered "obvious," in light of previous patents.

• Apple petitioned the PTAB in January 2021 to cancel the entire '484 patent, arguing that the prior inventions rendered it obvious.

• Federal Circuit precedent required the PTAB to consider the argument and evidence that Apple Inc. raised in a reply because Omni had advanced new claims construction position in its response, the appellate court ruled. For more, read the full Bloomberg Law report.

In January 2020, Patently Apple posted a report titled "Omni MedSci files a second Patent Infringement case against Apple that claims Apple Watch uses their technology." Our report covered the legal filing by Omni MedSci wherein they noted their patent covering the detection of blood glucose as highlighted below.

(Click on image to Enlarge)

This victory for Apple against Omni MedSci may allow them to continue their work on delivering blood glucose monitoring for Apple Watch. This could be a killer application for Apple Watch if it's proven to provide those with Type 2 diabetes with accurate glucose counts.

Side Note: Our cover graphic is from our July 2021 report titled "Apple won a Major Patent for an 'Integrated Photonics Device' that could be used in a Future Apple Watch for Monitoring Blood Glucose+."